Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 31,000 shares of the company’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $22.72, for a total transaction of $704,320.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Tyler Dylan-Hyde also recently made the following trade(s):

  • On Tuesday, January 2nd, Tyler Dylan-Hyde sold 38,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.64, for a total transaction of $822,320.00.
  • On Friday, December 28th, Tyler Dylan-Hyde sold 700 shares of Crispr Therapeutics stock. The shares were sold at an average price of $21.75, for a total transaction of $15,225.00.
  • On Friday, December 22nd, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.55, for a total transaction of $308,250.00.
  • On Friday, December 15th, Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.90, for a total transaction of $283,500.00.

Crispr Therapeutics AG (CRSP) opened at $25.77 on Thursday. Crispr Therapeutics AG has a twelve month low of $11.63 and a twelve month high of $28.50. The firm has a market capitalization of $1,060.00 and a price-to-earnings ratio of -80.53.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. Crispr Therapeutics’s quarterly revenue was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.77) EPS. sell-side analysts expect that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Hershey Trust Co. bought a new stake in Crispr Therapeutics in the 3rd quarter worth about $768,000. Tiff Advisory Services Inc. bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $505,000. Granahan Investment Management Inc. MA grew its holdings in shares of Crispr Therapeutics by 51.7% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after purchasing an additional 89,839 shares during the last quarter. Adams Street Partners LLC bought a new stake in Crispr Therapeutics in the 3rd quarter worth $1,019,000. Finally, Allianz Asset Management GmbH bought a new stake in Crispr Therapeutics in the 3rd quarter worth $2,384,000. 24.52% of the stock is owned by institutional investors.

A number of research analysts have recently commented on CRSP shares. Piper Jaffray Companies restated a “buy” rating and issued a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday. BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Oppenheimer restated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, December 21st. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Finally, SunTrust Banks reissued a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a research report on Friday, November 10th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $22.81.

TRADEMARK VIOLATION NOTICE: “Tyler Dylan-Hyde Sells 31,000 Shares of Crispr Therapeutics AG (NASDAQ:CRSP) Stock” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thelincolnianonline.com/2018/01/11/tyler-dylan-hyde-sells-31000-shares-of-crispr-therapeutics-ag-crsp-stock-updated.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Crispr Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.